OMEROS CORP

Omeros (OMER) edges up 3.69% after a steep decline, trading above its 200‑day SMA and hinting at cautious optimism; investors weigh its diversified pipeline and recent rally against peers like Millerknoll and Conmed.

Omeros (OMER) shares rose 1.22% to $16.26, but a 10.5% drop since March highlights volatility. With a diverse therapeutic pipeline, investors await key clinical data and regulatory milestones.